PDF(Pubmed)
Abstract：
BACKGROUND: Similar to many countries, Belgium experienced a rapid increase in cancer diagnoses in the last years. Considering that a large part of cancer types could be prevented, our study aimed to estimate the annual healthcare burden of cancer per site, and to compare cost with burden of disease estimates to have a better understanding of the impact of different cancer sites in Belgium.
METHODS: We used nationally available data sources to estimate the healthcare expenditure. We opted for a prevalence-based approach which measures the disease attributable costs that occur concurrently for 10-year prevalent cancer cases in 2018. Average attributable costs of cancer were computed via matching of cases (patients with cancer by site) and controls (patients without cancer). Years of life lost due to disability (YLD) were used to summarize the health impact of the selected cancers.
RESULTS: The highest attributable cost in 2018 among the selected cancers was on average €15,867 per patient for bronchus and lung cancer, followed by liver cancer, pancreatic cancer, and mesothelioma. For the total cost, lung cancer was the most costly cancer site with almost €700 million spent in 2018. Lung cancer was followed by breast and colorectal cancer that costed more than €300 million each in 2018.
CONCLUSIONS: In our study, the direct attributable cost of the most prevalent cancer sites in Belgium was estimated to provide useful guidance for cost containment policies. Many of these cancers could be prevented by tackling risk factors such as smoking, obesity, and environmental stressors.
METHODS: We used nationally available data sources to estimate the healthcare expenditure. We opted for a prevalence-based approach which measures the disease attributable costs that occur concurrently for 10-year prevalent cancer cases in 2018. Average attributable costs of cancer were computed via matching of cases (patients with cancer by site) and controls (patients without cancer). Years of life lost due to disability (YLD) were used to summarize the health impact of the selected cancers.
RESULTS: The highest attributable cost in 2018 among the selected cancers was on average €15,867 per patient for bronchus and lung cancer, followed by liver cancer, pancreatic cancer, and mesothelioma. For the total cost, lung cancer was the most costly cancer site with almost €700 million spent in 2018. Lung cancer was followed by breast and colorectal cancer that costed more than €300 million each in 2018.
CONCLUSIONS: In our study, the direct attributable cost of the most prevalent cancer sites in Belgium was estimated to provide useful guidance for cost containment policies. Many of these cancers could be prevented by tackling risk factors such as smoking, obesity, and environmental stressors.
摘要：
背景：与许多国家相似，比利时在过去几年中经历了癌症诊断的快速增长。考虑到很大一部分癌症是可以预防的，我们的研究旨在估计每个地点的癌症年度医疗负担，并将费用与疾病负担估计进行比较，以更好地了解比利时不同癌症部位的影响。
方法：我们使用全国可用的数据源来估算医疗支出。我们选择了基于患病率的方法，该方法测量2018年10年流行癌症病例同时发生的疾病可归因成本。癌症的平均可归因成本通过匹配病例(按部位患有癌症的患者)和对照(没有癌症的患者)来计算。使用因残疾而丧失的寿命(YLD)来总结所选癌症对健康的影响。
结果：在选定的癌症中，2018年的最高归因费用平均为支气管和肺癌患者15,867欧元，其次是肝癌，胰腺癌,和间皮瘤。对于总成本，肺癌是最昂贵的癌症部位，2018年花费了近7亿欧元。肺癌紧随其后的是乳腺癌和结直肠癌，2018年各花费超过3亿欧元。
结论：在我们的研究中，据估算,比利时最普遍癌症部位的直接归因成本为成本控制政策提供了有用的指导.这些癌症中的许多可以通过解决吸烟等风险因素来预防。肥胖，和环境压力。
方法：我们使用全国可用的数据源来估算医疗支出。我们选择了基于患病率的方法，该方法测量2018年10年流行癌症病例同时发生的疾病可归因成本。癌症的平均可归因成本通过匹配病例(按部位患有癌症的患者)和对照(没有癌症的患者)来计算。使用因残疾而丧失的寿命(YLD)来总结所选癌症对健康的影响。
结果：在选定的癌症中，2018年的最高归因费用平均为支气管和肺癌患者15,867欧元，其次是肝癌，胰腺癌,和间皮瘤。对于总成本，肺癌是最昂贵的癌症部位，2018年花费了近7亿欧元。肺癌紧随其后的是乳腺癌和结直肠癌，2018年各花费超过3亿欧元。
结论：在我们的研究中，据估算,比利时最普遍癌症部位的直接归因成本为成本控制政策提供了有用的指导.这些癌症中的许多可以通过解决吸烟等风险因素来预防。肥胖，和环境压力。
